The chair of Bausch Health (NYSE:BHC), Joe Papa, has resigned. The company has named the billionaire hedge fund manager John Paulson to assume the role. In an announcement, Bausch Health noted that the decision for Papa to resign was “not due to any dispute or disagreement” with the company or board. In May, Bausch Health…
Bausch + Lomb makes its stock market debut
After Bausch Health (NYSE:BHC) spun out its eye care unit Bausch + Lomb Corp. (NYSE/TSX:BLCO), its stock dipped 4.3% to $16.04 while BLCO shares increased 8.11% to $20.00 from a starting price of $18.00 per share. The $18 price tag was short of Wall Street’s expectations. The initial public offering was one of the first…
Bausch Health to fork over $300 million in diabetes antitrust lawsuit
Bausch Health (NYSE/TSX:BHC), formerly known as Valeant Pharmaceuticals, has agreed to pay $300 million to settle allegations that the company paid rivals to keep a generic version of Glumetza off the market. In 2015, the Laval, Canada–based company increased the drug’s price by almost eight-fold. The plaintiffs, drug distributor companies, in the class-action suit filed…